Interaction between active ruthenium complex [RuCl3(dppb)(VPy)] and phospholipid Langmuir monolayers: Effects on membrane electrical properties

Nanoarchitectonics and Simulation on the Molecular-Level Interactions between p-Sulfonic Acid Calix[4]arene and Langmuir Monolayers Representing Healthy and Cancerous Cell Membranes

The design of chemotherapeutic drug carriers requires precise information on their interaction with the plasma membrane since the carriers should be internalized by cells without disrupting or compromising the overall integrity of the membrane. In this study, we employ Langmuir monolayers mimicking the outer leaflet of plasma membranes of healthy and cancerous cells to determine the molecular-level interactions with a water-soluble calixarene derivative, p-sulfonic acid calix[4]arene (SCX4), which is promising as drug carrier. The cancer membrane models comprised either 40% 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 30% cholesterol (Chol), 20% 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), and 10% 1,2-dipalmitoyl-sn-glycero-3-phospho-l-serine (DPPS). The healthy membrane models were composed of 60% DPPC or DOPC, 30% Chol, and 10% DPPE. SCX4 expanded the surface pressure isotherms and decreased compressional moduli in all membrane models, altering their morphologies as seen in Brewster angle microscopy images. A combination of polarization-modulated infrared reflection absorption spectroscopy and molecular dynamics simulations revealed that SCX4 interacts preferentially with lipid headgroups in cancer membrane models through electrostatic interactions with the amine groups of DPPS and DPPE. In healthy membrane models, SCX4 interacts mostly with cholesterol through van der Waals forces. Using a multidimensional projection technique to compare data from the distinct membrane models, we observed that SCX4 effects depend on membrane composition with no preference for cancer or healthy membrane models, which is consistent with its biocompatibility. Furthermore, the interactions and close location of SCX4 to the headgroups indicate that it does not compromise membrane integrity, confirming that SCX4 may be a suitable drug carrier.

Effects induced by η6-p-cymene ruthenium(II) complexes on Langmuir monolayers mimicking cancer and healthy cell membranes do not correlate with their toxicity

The mechanism of chemotherapeutic action of Ru-based drugs involves plasma membrane disruption and valuable insights into this process may be gained using cell membrane models. The interactions of a series of cytotoxic η6-p-cymene ruthenium(II) complexes, [Ru(η6-p-cymene)P(3,5-C(CH3)3-C6H3)3Cl2] (1), [Ru(η6-p-cymene)P(3,5-CH3-C6H3)3Cl2] (2), [Ru(η6-p-cymene)P(4-CH3O-3,5-CH3-C6H2)3Cl2] (3), and [Ru(η6-p-cymene)P(4-CH3O-C6H4)3Cl2] (4), were examined using Langmuir monolayers as simplified healthy and cancerous outer leaflet plasma membrane models. The cancerous membrane (CM1 and CM2) models contained either 40 % 1,2- dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 30 % cholesterol (Chol), 20 % 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), and 10 % 1,2-dipalmitoyl-sn-glycero-3-phospho-l-serine (DPPS). Meanwhile, the healthy membrane (HM1 and HM2) models were composed of 60 % DPPC or DOPC, 30 % Chol and 10 % DPPE. The complexes affected surface pressure isotherms and decreased compressional moduli of cancerous and healthy membrane models, interacting with the monolayers headgroup and tails according to data from polarization-modulated infrared reflection absorption spectroscopy (PM-IRRAS). However, the effects did not correlate with the toxicity of the complexes to cancerous and healthy cells. Multidimensional projection technique showed that the complex (1) induced significant changes in the CM1 and HM1 monolayers, though it had the lowest cytotoxicity against cancer cells and is not toxic to healthy cells. Moreover, the most toxic complexes (2) and (4) were those that least affected CM2 and HM2 monolayers. The findings here support that the ruthenium complexes interact with lipids and cholesterol in cell membrane models, and their cytotoxic activities involve a multifaceted mode of action beyond membrane disruption.

Challenges in Application of Langmuir Monolayer Studies To Determine the Mechanisms of Bactericidal Activity of Ruthenium Complexes

The effects induced by antibiotics on the bacterial membrane may be correlated with their bactericidal activity, and such molecular-level interactions can be probed with Langmuir monolayers representing the cell membrane. In this study, we investigated the interaction between [Ru(mcbtz)₂(PPh₃)₂] (RuBTZ, mcbtz = 2-mercaptobenzothiazoline) and [Ru(mctz)₂(PPh₃)₂] (RuCTZ, mctz = 2-mercaptothiazoline) with Langmuir monolayers of a lipid extract of Escherichia coli, an extract of lipopolysaccharides (LPSs), and a zwitterionic phospholipid, dioleoylphosphatidyl choline (DOPC). RuBTZ and RuCTZ had little effects on DOPC, which is consistent with their negligible toxicity toward mammalian cells that may be approximated by a zwitterionic monolayer. Also little were their effects on LPSs. In contrast, RuBTZ and RuCTZ induced expansion in the surface pressure isotherms and decreased the compressional modulus of the E. coli lipid extract. While the more hydrophobic RuBTZ seemed to affect the hydrophobic tails of the E. coli extract monolayer to a larger extent, according to polarization modulation infrared reflection absorption spectroscopy results, evidence of a stronger RuBTZ interaction could not be confirmed unequivocally. Therefore, the interaction with the E. coli cell membrane cannot be directly correlated with the observed higher bactericidal activity of RuBTZ, in comparison to that of RuCTZ. This appears to be a case in which Langmuir monolayer studies do not suffice to determine the mechanisms responsible for the bactericidal activity.